Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 7/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | MARK3 | P27448 | 1/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440413 | 1.00 | PAK1 (0.35) | PAK1PIM2FLT3ROCK2TRPV1 | |
| SCHEMBL4440409 | 1.00 | PAK1 (0.35) | PAK1PIM2FLT3ROCK2TRPV1 | |
| SCHEMBL4443791 | 0.92 | PAK1 (0.35) | PAK1PIM2TRPV1GSK3B | |
| SCHEMBL4443531 | 0.92 | PAK1 (0.35) | PAK1PIM2TRPV1GSK3B | |
| SCHEMBL4443519 | 0.92 | PAK1 (0.35) | PAK1PIM2TRPV1GSK3B | |
| Hydrochloric Acid SCHEMBL5956850 | 0.91 | PAK1 (0.34) | PAK1PIM2ROCK2TRPV1GSK3B | |
| SCHEMBL4442272 | 0.86 | ROCK2 (0.48) | FLT3ROCK2CITPRKD3MAP4K4 | |
| SCHEMBL4442306 | 0.86 | ROCK2 (0.48) | FLT3ROCK2CITPRKD3MAP4K4 | |
| SCHEMBL4442264 | 0.86 | ROCK2 (0.48) | FLT3ROCK2CITPRKD3MAP4K4 | |
| SCHEMBL4440215 | 0.85 | NPC1 (0.39) | PAK1FLT3ROCK2TRPV1CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| WO-2008049000-A2 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | PAK1 59/4885PIM2 597/4885FLT3 891/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | PAK1 187/4885PIM2 2230/4885FLT3 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.